Sydney, Australia - 4 October 2018 – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company today announced the appointment of Dr Josep Tabernero, the President of the European Society for Medical Oncology, to its Scientific Advisory Board.
The European Society for Medical Oncology (ESMO) is the world’s leading professional organisation for medical oncology with 18,000 members representing 150 countries.
Imugene Managing Director and CEO Leslie Chong said, “I am honoured to have such a world leading oncologist and researcher join Imugene’s Scientific Advisory Board. Dr Tabernero is accepted globally as a leader in oncology research and I am priviledged to continue to work with him to develop Imugene’s technology. The calibre of recent appointments to our SAB underlines the strong and widespread international interest in the therapeutic potential of our promising B-cell cancer immuno-therapy strategy and pipeline.”
For further information please download PDF attached:
Download this document